Perspective Therapeutics’ (CATX) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a research report report published on Monday,RTT News reports. The brokerage currently has a $11.00 price objective on the stock.

Several other brokerages also recently issued reports on CATX. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research note on Saturday, July 12th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research note on Friday, October 3rd. BTIG Research assumed coverage on Perspective Therapeutics in a research note on Friday, October 10th. They issued a “buy” rating and a $14.00 price objective for the company. Finally, B. Riley reissued a “buy” rating and issued a $12.00 price objective (up from $9.00) on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Four equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $12.70.

Perspective Therapeutics Price Performance

Shares of NYSEAMERICAN CATX opened at $3.01 on Monday. Perspective Therapeutics has a 12 month low of $1.60 and a 12 month high of $12.90. The company has a quick ratio of 15.09, a current ratio of 15.09 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $3.59 and a 200-day simple moving average of $3.25.

Institutional Investors Weigh In On Perspective Therapeutics

Several institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets lifted its holdings in shares of Perspective Therapeutics by 227.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 242,610 shares of the company’s stock valued at $835,000 after buying an additional 168,448 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Perspective Therapeutics by 8.5% during the 2nd quarter. Bank of America Corp DE now owns 327,500 shares of the company’s stock valued at $1,127,000 after buying an additional 25,697 shares during the last quarter. Federated Hermes Inc. lifted its holdings in shares of Perspective Therapeutics by 44.4% during the 2nd quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock valued at $671,000 after buying an additional 60,019 shares during the last quarter. Walleye Capital LLC lifted its holdings in shares of Perspective Therapeutics by 375.8% during the 2nd quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock valued at $645,000 after buying an additional 148,013 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Perspective Therapeutics by 118.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock valued at $2,573,000 after buying an additional 405,612 shares during the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.